Geng Jia

发表

First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation.

C. Chou, Xiaoyang Li, Kairui Yue, 2022, Journal of medicinal chemistry.

Targeted Drug Conjugates in Cancer Therapy: Challenges and Opportunities

Geng Jia, Yuqi Jiang, Xiaoyang Li, 2024, Pharmaceutical Science Advances.

Biological function and small molecule inhibitors of histone deacetylase 11.

Yuqi Jiang, Geng Jia, Xiaoyang Li, 2024, European journal of medicinal chemistry.